Treatment of pd-l1-positive melanoma using an Anti-pd-1 antibody

Abstract

The invention provides a method of treating a melanoma comprising (i) identifying a patient having a PD-L1 positive melanoma and (ii) administering to the patient an anti-PD-1 antibody or an antigen-binding portion thereof (“an anti-PD-1 antibody monotherapy”). The methods of the invention can extend progression-free survival for over 12 months and / or reduces the tumor size at least about 10%, about 20%, about 30%, about 40%, or about 50% compared to the tumor size prior to the administration.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS[0001]The present application claims benefit to U.S. Provisional Application No. 62 / 153,954 filed Apr. 28, 2015, which is incorporated herein by reference in its entirety.REFERENCE TO A SEQUENCE LISTING SUBMITTED ELECTRONICALLY VIA EFS-WEB[0002]The instant application contains a Sequence Listing which has been submitted in ASCII format via EFS-Web, and is hereby incorporated by reference in its entirety. Said ASCII copy, created on Jun. 3, 2019, is named 3338_0320003_Seqlisting_ST25 and is 3,742 bytes in size.[0003]Throughout this application, various publications are referenced in parentheses by author name and date, or by Patent No. or Patent Publication No. The disclosures of these publications are hereby incorporated in their entireties by reference into this application in order to more fully describe the state of the art as known to those skilled therein as of the date of the invention described and claimed herein. However, the citation o...

AI Technical Summary

Benefits of technology

[0012]The present disclosure also provides a method for reducing a tumor size at least by 10% in a patient afflicted with a melanoma tumor comprising administering to the patient an anti-PD-1 antibody monotherapy, wherein the patient is identified as having a melanoma tumor expressing PD-L1 prior to the administration and wherein the administration reduces the tumor size at least about 10%, about 20%, about 30%, about 40%, or about 50% compared to the tumor size prior to the administration.

Problems solved by technology

However, unlike the clinical development of small molecule agents that target discrete activating mutations found in select cancer populations, a particular challenge in cancer immunotherapy has been the identification of mechanism-based predictive biomarkers to enable patient selection and guide on-treatment management.

Images